Cargando…

Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA

Detalles Bibliográficos
Autores principales:	Zeng, Weihong, Ma, Huan, Ding, Chengchao, Yang, Yunru, Sun, Yong, Huang, Xiaoxue, He, Weihuang, Xiang, Yan, Gao, Yong, Jin, Tengchuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844101/ https://www.ncbi.nlm.nih.gov/pubmed/33514692 http://dx.doi.org/10.1038/s41392-021-00478-7

Ejemplares similares

Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
por: Ma, Huan, et al.
Publicado: (2021)

Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge
por: Ma, Huan, et al.
Publicado: (2020)

Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2
por: Klingler, Jéromine, et al.
Publicado: (2020)

Serum IgA, IgM, and IgG responses in COVID-19
por: Ma, Huan, et al.
Publicado: (2020)

IgA dominates the early neutralizing antibody response to SARS-CoV-2
por: Sterlin, Delphine, et al.
Publicado: (2021)

Biochemical characterization of SARS-CoV-2 nucleocapsid protein
por: Zeng, Weihong, et al.
Publicado: (2020)

Corrigendum to “Biochemical characterization of SARS-CoV-2 nucleocapsid protein”
por: Zeng, Weihong, et al.
Publicado: (2022)

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2
por: Planchais, Cyril, et al.
Publicado: (2022)

IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection
por: Quinti, Isabella, et al.
Publicado: (2021)

Enhanced SARS-CoV-2 neutralization by dimeric IgA
por: Wang, Zijun, et al.
Publicado: (2021)

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
por: Kombe Kombe, Arnaud John, et al.
Publicado: (2021)

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro
por: Wang, Zijun, et al.
Publicado: (2020)

Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples
por: Mazzini, Livia, et al.
Publicado: (2021)

Salivary IgAs and Their Role in Mucosal Neutralization of SARS-CoV-2 Variants of Concern
por: Diem, Gabriel, et al.
Publicado: (2022)

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
por: Xie, Jiajia, et al.
Publicado: (2021)

The Potential Role of an Aberrant Mucosal Immune Response to SARS-CoV-2 in the Pathogenesis of IgA Nephropathy
por: Zhang, Zhao, et al.
Publicado: (2021)

IgA quantification as a good predictor of the neutralizing antibodies levels after vaccination against SARS-CoV-2
por: Fernandes-Siqueira, Lorena O., et al.
Publicado: (2022)

Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG
por: Sun, Lin, et al.
Publicado: (2021)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region?
por: Pisil, Yalcin, et al.
Publicado: (2021)

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
por: Nihei, Yoshihito, et al.
Publicado: (2023)

Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG
Publicado: (1985)

SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on
por: Korte, Wolfgang, et al.
Publicado: (2021)

IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
por: Hale, Malika, et al.
Publicado: (2022)

IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern
por: Chang, Matthew R., et al.
Publicado: (2022)

Systemic administration of an HIV 1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization
por: Fouda, Genevieve G., et al.
Publicado: (2016)

The IgA in milk induced by SARS-CoV-2 infection is comprised of mainly secretory antibody that is neutralizing and highly durable over time
por: Fox, Alisa, et al.
Publicado: (2022)

Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine
por: Pitcovski, Jacob, et al.
Publicado: (2022)

Recombinant IgA Antibodies
por: Yoo, Esther M., et al.
Publicado: (2007)

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
por: Zhang, Xinghai, et al.
Publicado: (2022)

Potently neutralizing and protective human antibodies against SARS-CoV-2
por: Zost, Seth J., et al.
Publicado: (2020)

VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA
por: Jia, Manxue, et al.
Publicado: (2020)

SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters(1)
por: Zhou, Biao, et al.
Publicado: (2023)

Heterologous SARS‐CoV‐2 IgA neutralising antibody responses in convalescent plasma
por: Davis, Samantha K, et al.
Publicado: (2022)

Human IgA Monoclonal Antibodies That Neutralize Poliovirus, Produced by Hybridomas and Recombinant Expression
por: Puligedda, Rama Devudu, et al.
Publicado: (2020)

IgA pemphigus showing IgA antibodies to desmoglein 1 and 3
por: Hegazy, Salama, et al.
Publicado: (2016)

Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies
por: Beavis, Kathleen G., et al.
Publicado: (2020)

Correction: IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
por: Hale, Malika, et al.
Publicado: (2022)

Correlation between the IgG/IgA Antibody Response against PEDV Structural Protein and Virus Neutralization
por: Song, Xu, et al.
Publicado: (2023)

The serological diversity of serum IgG/IgA/IgM against SARS‐CoV‐2 nucleoprotein, spike, and receptor‐binding domain and neutralizing antibodies in patients with COVID‐19 in Japan
por: Kaneko, Yudai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mvss1uhvgfkpri5kj3t88t6qa1